A series of cardiometabolic-related news items has been observed from Arrowhead, Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Structure Therapeutics announced updated results from its aleniglipron Ph2 obesity ACCESS trials (view press release; view slides); Lilly announced Zepbound KwikPen is now available for cash-pay patients via LillyDirect and retail pharmacies (view press release); and Bayer announced positive topline results from the Ph3 finerenone FIND-CKD study in non-T2DM CKD (view press release). Below, FENIX provides highlights and insights from the respective news items.
Two cardiometabolic-related news items have been observed: Structure released its Q4 ’25 earnings report (press release), and the CHMP highlights for this month’s meeting (February 23-26) have been released (view highlights). Below, FENIX provides highlights and insights for the respective news items.
A series of cardio-metabolic-related news items has been observed from Structure Therapeutics, Ascletis Pharma, Boehringer Ingelheim, Wave Life Sciences, Abbott, and Medtronic. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: MIRA Pharmaceuticals acquired SKNY Pharmaceuticals, including its lead CB1 inhibitor for obesity and addiction (view press release); and Structure Therapeutics initiated its Ph2 study evaluating aleniglipron on body composition in participants with obesity (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.